links.lww.com/EJGH/A149

Suppl. Table 1: Baseline Characteristics according to listing diagnosis (prior to histological re-classification)

Cryptogenic cirrhosis

NASH p-value

Patients [n] 14 13

Age [years], mean (±SEM) 52.36 (±2.72) 59.54 (±2.21) p=0.0051

Sex [M/F, % male] 11 (78.6%) 10 (76.9%) p= 0.9180

BMI [kg/m²], mean (±SEM) 24.84 (±0.99) 27.62 (±1.27) p=0.0933

Diabetes mellitus 4 (28.57%) 4 (30.77%) p=0.9006

Hepatic Malignancy 3 (21.43%) 5 (38.46%) p=0.3328

Portal vein thrombosis

[n (%)] 3 (21.43%) 1 (7.69%) p=0.3154

HE Grade III / IV [n (%)] 7 (50.0%) 4 (30.77%) p=0.3096

Ascites [n (%)] 9 (64.29%) 12 (92.31%) p=0.0801

Bilirubin [mg/dl], mean (±SD)

8.00 (±9.40) 4.29 (±2.85) p=0.2024

Albumin [g/l], mean (±SD) 33.54 (±7.98) 30.88 (±7.52) p=0.4183 PTT [%], mean (±SD) 54.26 (±19.29) 46.46 (±15.89) p=0.2904 MELD (Listing), mean (±SD) 15.85 (±4.39) 14.88 (±3.07) p=0.5138 MELD (OLT), mean (±SD) 17.52 (±6.34) 18.01 (±5.18) p=0.8374 PLT [G/l], mean (±SD) 94.29 (±33.24) 80.69 (±26.97) p=0.2743 ALT [U/l], mean (±SD) 67.54 (±57.88) 46.46 (±20.64) p=0.2464 AST [U/l], mean (±SD) 106.92 (±90.21) 76.25 (±28.45) p=0.2908 GGT [U/l], mean (±SD) 269.77 (±399.11) 168.67 (±204.37) p=0.4578 Total Cholesterol (Listing)

[mg/dl], mean (±SD)

153.15 (±48.15) 169.08 (±37.12) p=0.3862

Triglycerides (Listing) [mg/dl]

mean (±SD) 105.08 (±30.82) 109.58 (±43.61) p=0.7760

HDL [mg/dl] (Listing), mean (±SD)

32.31 (±13.59) 48.58 (±16.32) p=0.0158 LDL [mg/dl] (Listing),

mean (±SD) 107.97 (±39.14) 98.58 (±32.30) p=0.5385

Laboratory parameters were recorded on the date of liver transplantation except otherwise specified. Groups showed no statistically significant difference in baseline characteristics except for age, BMI and HDL blood levels. (SEM) standard error of the mean, (SD) standard deviation.

Supplementary Table-S2

Patients with NFS>0.676 after OLT

(n=2)

Patients with NFS<0.676 and NFS

>-1.455 after OLT (n=7)

Patients with NFS<-1.455 after OLT (n=5)

p-values

Age (years) 63 (±0.0) 57.7 (±3.4) 49.0 (±5.4) p=0.2055

Male Gender (n, %) 2 (100%) 5 (71.4%) 4 (80%) p=0.6826

HDL [mg/dl], Mean ±SEM 35.0 (±3,0) 37.4 (±6.9) 48.0 (±7.5) p=0.5088 LDL[mg/dl], Mean ±SEM 166.0 (±4.9) 115.1 (±9.5) 80.8 (±8.5) p=0.0022

Triglycerides [mg/dl], Mean ±SEM

668.0 (±103.0) 252.7 (±65.1) 150.0 (±47.8) p=0.0053

Diabetes (n, %) 1 (50%) 3 (42.9%) 0 (0%) p=0.2070

Hypertension (n, %) 1 (50%) 3 (42.9%) 1 (20%) p=0.6469

Steroid duration [days], Mean ±SEM

425.5 (±304.5) 290.1 (±83.6) 299.8 (±34.2) p=0.7281

Serum Creatinine [mg/dl], Mean ±SEM

1.6 (±0.1) 1.3 (±0.1) 1.3 (±0.2) p=0.4662

Table-S1: Patients with significant fibrosis according to the NAFLD fibrosis score

had significantly higher serum LDL and triglyceride levels than patients without

significant fibrosis according to NAFLD fibrosis scores.